Top 5 Papers
#1
Source: Nature Cancer | Authors: Li C, Ke F, Zhao H, et al. | Published: April 28, 2026
Score: 10/20 — Base 9 (Nature Cancer) + 1 (biomarker-guided/precision)
This study identifies PI3Kγ as a critical dependency of STING agonist–expanded regulatory B cells in pancreatic cancer, while STING-activated myeloid cells remain PI3Kγ-independent. The authors developed Nano-273, an albumin nanoformulation that simultaneously stimulates STING to activate myeloid cells and inhibits PI3Kγ to block Breg expansion. Nano-273 effectively delivered to tumors and lymph nodes, overcoming dual myeloid/Breg immunosuppression. Combined with anti-PD-1, Nano-273 achieved durable efficacy in transgenic KPC mice, offering a novel therapeutic strategy for pancreatic cancer immunotherapy.
Post angle: Finally a strategy that tackles BOTH myeloid AND B cell immunosuppression in PDAC! Nano-273 + anti-PD-1 = durable responses in KPC mice. This dual PI3Kγ/STING approach could change how we think about PDAC immunotherapy. #PDAC #Immunotherapy #PrecisionMedicine #GIOnc
#2
Source: Nature Reviews Clinical Oncology | Authors: Lee DJ, Parikh A, Sirohi B, Cao Y, Chan AT | Published: April 28, 2026
Score: 9/20 — Base 9 (Nature Reviews Clinical Oncology / Lancet-tier journal)
This comprehensive review in Nature Reviews Clinical Oncology examines the shifting global epidemiology of colorectal cancer, highlighting the alarming rise in early-onset CRC in individuals under 50 years old. A birth cohort effect beginning with those born in the 1960s suggests environmental rather than genetic drivers. Key hypothesized risk factors include dietary changes, gut microbiome shifts, and environmental contaminants linked to rapid urbanization. The authors emphasize that under-representation of non-Western populations in genomic and epigenomic studies limits progress in global CRC prevention and control.
Post angle: Essential reading: early-onset CRC is rising GLOBALLY, not just in the West. Birth cohort data points to environmental drivers beyond genetics. Until we include diverse populations in our research, we're flying blind on prevention. #CRC #EarlyOnsetCRC #GIOnc #CancerPrevention
#3
Source: Gut | Authors: Li Q, Yu K, Zhou S, et al. | Published: April 28, 2026
Score: 9/20 — Base 8 (Gut, top-tier GI journal) + 1 (biomarker-guided/precision)
This multi-omics study reveals that deubiquitinase JOSD1 orchestrates a ubiquitination-to-lactylation PTM switch on PGAM1 via the JOSD1-AARS1 axis, driving glycolytic reprogramming in HCC. Stabilized PGAM1 enhances lactate accumulation, which impairs CD8+ T cell infiltration and function, creating an immunosuppressive microenvironment. Liver-targeted JOSD1 inhibition suppressed tumor progression and synergized with anti-PD-1 therapy, prolonging survival in preclinical models. This identifies JOSD1 as a druggable metabolic-immune checkpoint in HCC.
Post angle: A metabolic-immune master switch in HCC: JOSD1 flips PGAM1 from ubiquitination → lactylation, fueling glycolysis and killing CD8+ T cells. Targeting JOSD1 + anti-PD-1 = synergy in preclinical models. New druggable target alert! #HCC #LiverCancer #Immunotherapy #GIOnc
#4
Source: Cell Discovery | Authors: Bai J, Geng D, Chen X, et al. | Published: April 28, 2026
Score: 7/20 — Base 6 (Cell Discovery) + 1 (biomarker-guided/precision)
Using untargeted plasma metabolomics, this study found serotonin (5-HT) levels are significantly elevated in gastric cancer patients and promote tumor growth dose-dependently. The oncogenic mechanism is receptor-independent: transglutaminase 2 (TGM2) serotonylates GPX4 at Gln55 and Gln77, stabilizing GPX4 by blocking ubiquitin-mediated degradation and conferring ferroptosis resistance. Chemoproteomic profiling identified a broad spectrum of serotonylation targets beyond GPX4. TGM2 levels correlated with GPX4 expression clinically, establishing TGM2-mediated GPX4 serotonylation as a novel diagnostic biomarker and therapeutic target within the neural-tumor axis.
Post angle: The gut-brain-cancer connection gets real: serotonin directly fuels gastric cancer growth via a novel protein serotonylation mechanism. TGM2 modifies GPX4 → ferroptosis resistance → tumor growth. A whole new layer of neural-tumor biology! #GastricCancer #Ferroptosis #GIOnc
#5
Source: Signal Transduction and Targeted Therapy | Authors: MARCO study authors (STTT) | Published: April 28, 2026
Score: 7/20 — Base 6 (STTT) + 1 (biomarker-guided/precision)
This study demonstrates that the scavenger receptor MARCO is highly expressed on tumor-associated macrophages in cholangiocarcinoma, where it drives T cell dysfunction, fibrosis, and immunosuppression. High MARCO expression correlates with worse overall survival. Marco-knockout mice were protected from cholangiocarcinogenesis, and anti-MARCO antibody therapy significantly reduced tumor burden in preclinical models. These findings position MARCO as both a prognostic biomarker and a novel immunotherapeutic target in cholangiocarcinoma.
Post angle: New immunotherapy target in cholangiocarcinoma: MARCO on tumor macrophages drives T cell dysfunction + fibrosis. Anti-MARCO antibody shrinks tumors in preclinical models. Much-needed progress for a disease with limited options! #CCA #BiliaryCancer #Immunotherapy #GIOnc
Additional Papers of Interest
-
PNAS — Mic60-low mitochondria release dsRNA engaging TLR3/RIG-I → NFκB → PDAC proliferation; preclinical targeting inhibits tumor growth
-
Oncogene — ADH1B marks normal fibroblasts, ITGA3 delineates CAFs; TGF-β stably induces myCAFs while TNF-α promotes transient piCAF emergence in CRC
-
British Journal of Cancer — SLIRP knockdown triggers ATP crisis and tumor suppression; potential OXPHOS-targeted therapeutic strategy for CRC
-
Oncogene — OLFM4 activates TGFβ signaling and CEACAM6-mediated EMT to promote gallbladder cancer progression
-
PNAS — MFN1 impairment generates ROS gradients driving HCC/ICC differentiation in combined hepatocellular-cholangiocarcinoma
Back to all digests